Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Virax Biolabs Group Limit...

    NASDAQ: VRAX · Real-Time Price · USD
    0.82
    -0.05 (-5.78%)
    At close: Jun 17, 2025, 3:20 PM

    Virax Biolabs Statistics

    Share Statistics

    Virax Biolabs has 4.34M shares outstanding. The number of shares has increased by 83.83% in one year.

    Shares Outstanding

    n/a
    		 4.34M

    Shares Change (YoY)

    n/a
    		 83.83%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 3.14%

    Shares Floating

    n/a
    		 4.05M

    Failed to Deliver (FTD) Shares

    n/a
    		 271

    FTD / Avg. Volume

    n/a
    		 0.19%

    Short Selling Information

    The latest short interest is 49.14K, so 1.13% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 49.14K

    Short % of Shares Out

    n/a
    		 1.13%

    Short % of Float

    n/a
    		 1.21%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -0.22 and the forward PE ratio is -0.87. Virax Biolabs's PEG ratio is 0.01.

    PE Ratio

    n/a
    		 -0.22

    Forward PE

    n/a
    		 -0.87

    PS Ratio

    n/a
    		 9.43

    Forward PS

    n/a
    		 94.5

    PB Ratio

    n/a
    		 0.27

    P/FCF Ratio

    n/a
    		 -0.2

    PEG Ratio

    n/a
    		 0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Virax Biolabs.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 25.94, with a Debt / Equity ratio of 0.04.

    Current Ratio

    n/a
    		 25.94

    Quick Ratio

    n/a
    		 25.58

    Debt / Equity

    n/a
    		 0.04

    Debt / EBITDA

    n/a
    		 -0.03

    Debt / FCF

    n/a
    		 -0.03

    Interest Coverage

    n/a
    		 -241.7

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $9,201.12

    Profits Per Employee

    n/a
    		 $-396,090.41

    Employee Count

    n/a
    		 17

    Asset Turnover

    n/a
    		 0.03

    Inventory Turnover

    n/a
    		 1.75

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -49.42% in the last 52 weeks. The beta is 1.76, so Virax Biolabs's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.76

    52-Week Price Change

    n/a
    		 -49.42%

    50-Day Moving Average

    n/a
    		 1

    200-Day Moving Average

    n/a
    		 1.76

    Relative Strength Index (RSI)

    n/a
    		 34.17

    Average Volume (20 Days)

    n/a
    		 142,731

    Income Statement

    In the last 12 months, Virax Biolabs had revenue of 156.42K and earned -6.73M in profits. Earnings per share was -3.36.

    Revenue

    n/a
    		 156.42K

    Gross Profit

    n/a
    		 50.59K

    Operating Income

    n/a
    		 -6.5M

    Net Income

    n/a
    		 -6.73M

    EBITDA

    n/a
    		 -6.61M

    EBIT

    n/a
    		 -6.71M

    Earnings Per Share (EPS)

    n/a
    		 -3.36
    Full Income Statement

    Balance Sheet

    The company has 3.59M in cash and 224.3K in debt, giving a net cash position of 3.36M.

    Cash & Cash Equivalents

    n/a
    		 3.59M

    Total Debt

    n/a
    		 224.3K

    Net Cash

    n/a
    		 3.36M

    Retained Earnings

    n/a
    		 -18.53M

    Total Assets

    n/a
    		 9.44M

    Working Capital

    n/a
    		 7.34M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -6.25M and capital expenditures -1.16M, giving a free cash flow of -7.41M.

    Operating Cash Flow

    n/a
    		 -6.25M

    Capital Expenditures

    n/a
    		 -1.16M

    Free Cash Flow

    n/a
    		 -7.41M

    FCF Per Share

    n/a
    		 -3.69
    Full Cash Flow Statement

    Margins

    Gross margin is 32.34%, with operating and profit margins of -4153.25% and -4304.81%.

    Gross Margin

    n/a
    		 32.34%

    Operating Margin

    n/a
    		 -4153.25%

    Pretax Margin

    n/a
    		 -4308.38%

    Profit Margin

    n/a
    		 -4304.81%

    EBITDA Margin

    n/a
    		 -4225.28%

    EBIT Margin

    n/a
    		 -4153.25%

    FCF Margin

    n/a
    		 -4738.21%

    Dividends & Yields

    VRAX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for VRAX is $3, which is 244.8% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $3

    Price Target Difference

    n/a
    		 244.8%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Dec 18, 2023. It was a backward split with a ratio of 1:10.

    Last Split Date

    n/a
    		 Dec 18, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:10

    Scores

    Altman Z-Score

    n/a
    		 -4.45

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist